ArticleProtein science : a publication of the Protein Society2008
Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors.
Article in Protein science : a publication of the Protein Society, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 141 citations in OpenAlex.
- Pooled it
- Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled phase III trials.Clinical rheumatology · 2021Pooled it
- Pooled it
- Trial
- Tanezumab for the treatment of pain from osteoarthritis of the knee.The New England journal of medicine · 2010Trial
- Skin-Integrated Soft Wearable XR Interfaces for Seamless and Realistic User Experience.Chemical reviews · 2025Review
- Guselkumab binding to CD64Frontiers in immunology · 2025Article
- Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: a case study with bedinvetmab (Librela™).Frontiers in veterinary science · 2025Article
- Recent Advances in Management of Neuropathic, Nociceptive, and Chronic Pain: A Narrative Review with Focus on Nanomedicine, Gene Therapy, Stem Cell Therapy, and Newer Therapeutic Options.Current pain and headache reports · 2024Review
- Lessons learned in translating pain knowledge into practice.Pain reports · 2023Article
- Therapeutic Effect of HDAC5 Binding and Cell Penetrating Peptide for the Treatment of Inflammatory Bowel Disease.Tissue engineering and regenerative medicine · 2023Article
- Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor.CPT: pharmacometrics & systems pharmacology · 2023Article
- Analytical Method for Experimental Validation of Computer-Designed Antibody.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Effusion detected by ultrasonography and overweight may predict the risk of knee osteoarthritis in females with early knee osteoarthritis: a retrospective analysis of Iwaki cohort data.BMC musculoskeletal disorders · 2022Article
- Efficacy and Safety of Anti-Nerve Growth Factor Antibody Therapy for Hip and Knee Osteoarthritis: A Meta-analysis.Orthopaedic journal of sports medicine · 2022Review
- Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials.Therapeutic advances in musculoskeletal disease · 2022Article
- Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis.Biologics : targets & therapy · 2022Review
- New developments in osteoarthritis pharmacological therapies.Rheumatology (Oxford, England) · 2021Review
- Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions.Experimental & molecular medicine · 2021Review
- Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe the use of four complementary biosensors (Biacore 3000, Octet QK, ProteOn XPR36, and KinExA 3000) in characterizing the kinetics of human nerve growth factor (NGF) binding to a humanized NGF-neutralizing monoclonal antibody (tanezumab, formerly known as RN624). Tanezumab is a clinical candidate as a therapy for chronic pain. Our measurements were consistent with the NGF/tanezumab binding affinity being tighter than 10 pM due to the formation of an extremely stable complex that had an estimated half-life exceeding 100 h, which was beyond the resolution of any of our methods. The system was particularly challenging to study because NGF is an obligate homodimer, and we describe various assay orientations and immobilization methods that were used to minimize avidity in our experiments while keeping NGF in as native a state as possible. We also explored the interactions of NGF with its natural receptors, TrkA and P75, and how tanezumab blocks them. The Biacore blocking assay that we designed was used to quantify the potency of tanezumab and is more precise and reproducible than the currently available cell-based functional assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.